alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,626–1,650 of 2,174 studies in Risk factors (page 66 of 87) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

What “Risk factors” covers

Risk factors — Conditions, exposures and habits linked to a higher or lower chance of dementia, and how strong each link is.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Late-life depression with comorbid cognitive impairment and disability: nonpharmacological interventions

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Clinical interventions in aging 2010-11-15

Less than half of older adults with depression achieve remission with antidepressant medications, and rates of remission are even poorer for those with comorbid conditions. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications

✓ Peer-reviewed alzhub usefulness score 38 out of 100. NPG Asia Materials 2014-03-01

Cerium oxide nanoparticles (CeONPs) have attracted much attention because they possess multi-enzyme mimetic properties and have been used in bioanalysis, biomedicine, drug delivery, bioscaffold and so on. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

4430 Coffee Shops and Fast-food Restaurants: Potential Neighborhood Resources for Cognitive Health and Wellbeing Among Aging Americans

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Clinical and Translational Science 2020-06-01

OF IMPACT: The results contribute new evidence towards an emerging ecological model of cognitive health. 5 key findings →

Participants: 16,404 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Applying the Relational Job Design Theory to the Retail Industry: The Association between Perceived Social Impact and Job Satisfaction, Turnover Intention, and Persistence

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Health & Social Care in the Community 2024-01-01

Retail workers contribute to the daily wellbeing of customers, including those living with disabilities or diseases. 2 key findings →

Participants: 145 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Area Deprivation Index and Progression to Dementia (S2.007)

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Neurology 2022-05-03

To investigate the association of the area deprivation index (ADI), as assigned at the census block group-level, with progression to dementia in cognitively unimpaired at baseline participants (≥50 years old) of the population-based Mayo Clinic Study of Aging (MCSA). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Exploring hospital-based health information technology functions for patients with Alzheimer’s Disease and related Dementias

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Preventive Medicine Reports 2021-06-23

This study investigated whether hospital-adopted health information technology (HIT) is associated with a reduction in the frequency of preventable emergency department (ED) visits for patients with Alzheimer's Disease and Related Dementias (ADRD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between structural/social determinants of health and vulnerability for and resilience against Alzheimer’s disease and related dementias: The Healthy Brain Initiative

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2023-12-01

S/SDOH can significantly impact health throughout the life course by determining access to health promoting resources and opportunities, which in turn impacts modifiable risk factors (e.g., diet, physical activity, social contact) known to influence Alzheimer’s disease and related dementia (ADRD) risk. 5 key findings →

Participants: 111 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations of social determinants of health (SDOH) with dementia and mild cognitive impairment (MCI), the HABS‐HD Study

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2025-12-01

All the five dimensional SDOH disadvantages were significantly associated with higher odds of both dementia and MCI in the overall sample (p <0.05) (Figure 1). 5 key findings →

Participants: 3,229 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Neurology Neurosurgery & Psychiatry 2021-02-09

Since its first description by Charcot, amyotrophic lateral sclerosis (ALS) has been classified as a single neurodegenerative disease involving motor neurons. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Spatiotemporal trends in dementia‐associated deaths, what do the data reveal?

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2021-12-01

There are factors, other than the step changes in underlying cause of death coding, driving the progressively increasing temporal trend in relative risk of dementia‐associated death. 2 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Mapping healthcare utilization of people with Alzheimer’s Disease and Related Dementias to identify priority areas in the State of South Carolina

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2024-12-01

The findings from this study provide clear evidence that there is a greater need for resources to support SC residents with ADRD and their caregivers in the Pee Dee and Upstate regions. 1 key finding →

Participants: 115,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed